Arca
Skip to content
Tools
Tools

Ocular hypertension

Drug research and approvals for ocular hypertension: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 190 studies of ocular hypertension are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and the EU has 11 authorised medicines for it.

  • Recruiting worldwide: 190
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 0
  • EU medicines: 11

Recruiting now

Newest posted first, of 190 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 13

Phase 3 3

Phase 2 5

  • DE-104Rho-associated protein kinase inhibitor
  • AMA0076Rho-associated protein kinase inhibitor
  • VerosudilRho-associated protein kinase inhibitor
  • PiclidenosonAdenosine A3 receptor agonist
  • AZD-401711-beta-hydroxysteroid dehydrogenase 1 inhibitor

Phase 1 or earlier 5

How its trials ended

607 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 135 whose ending is known, 62% met their primary endpoint, 1% missed it and 36% stopped early.

  • Completed, result not reported38363%
  • Met its primary endpoint8414%
  • Status unknown488%
  • Ongoing417%
  • Stopped: other or unclear325%
  • Stopped: enrollment or feasibility61%
  • Stopped: sponsor or business decision61%
  • Stopped: funding3<1%
  • Missed its primary endpoint2<1%
  • Stopped: lack of efficacy2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Jul 10, 2026Clinical trial protocol title: a phase 1/2 study of REGN22530 in participants with primary open angle glaucoma or ocular hypertensionREGN22530RegeneronOngoing

Medicines authorised in the EU

Newest first
Nov 15, 2023CatiolanzeLatanoprostSanten OyEMA ↗
Jan 7, 2021RoclandaLatanoprost / netarsudilSanten OyEMA ↗
Nov 19, 2019RhokiinsaNetarsudilSanten OyEMA ↗
Jul 18, 2014SimbrinzaBrinzolamide; brimonidine tartrateNovartis Europharm LimitedEMA ↗
Feb 20, 2014IzbaTravoprostNovartis Europharm LimitedEMA ↗
Nov 25, 2008AzargaBrinzolamide; timololNovartis Europharm LimitedEMA ↗
May 19, 2006GanfortBimatoprost; timololAbbVie Deutschland GmbH & Co. KGEMA ↗
Apr 23, 2006DuoTravTravoprost; timololNovartis Europharm LimitedEMA ↗
Mar 8, 2002LumiganBimatoprostAbbVie Deutschland GmbH & Co. KGEMA ↗
Nov 27, 2001TravatanTravoprostNovartis Europharm LimitedEMA ↗
Mar 9, 2000AzoptBrinzolamideNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.